Literature DB >> 17350144

[Vogt-Koyanagi-Harada syndrome. Eight cases].

F-Z Alaoui1, S Benamour, H El Kabli, A Amraoui.   

Abstract

PURPOSE: Vogt-Koyanagi-Harada disease is a rare systemic affection characterised by the association of ocular inflammatory manifestations and extra ocular lesions such as meningismus, tegumentary or auditory findings observed in pigmented population. Auto-immune origin of this syndrome is probable; a T-lymphocyte-mediated autoimmune process is directed against an unidentified antigen associated with melanocytes.
METHODS: The aim of this retrospective study is to determine their clinical profile in our country.
RESULTS: Eight consecutive cases of Vogt-Koyanagi-Harada disease were studied during a 22-year period. All the patients fulfilled the criteria of American Uveitis Society. All patients were female and had bilateral ocular involvement as panuveitis. Retinal serous detachment was observed in 4 patients, meningitis in 6 cases. 7 patients had hearing loss and 5 patients had cutaneous lesions represented by poliosis. Corticosteroids and/or immunosuppressive therapy were administered in all patients leading to improvement in 5 patients.
CONCLUSION: Our series are concording with a usually good ocular prognosis. Immunosuppressive therapy should be used early in posterior segment involvement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350144     DOI: 10.1016/j.revmed.2006.12.009

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  2 in total

1.  [Vitiligo revealing Vogt -Koyanagi-Harada disease].

Authors:  Mohamed El Amraoui; Youssef Zemmez; Ahmed Bouhamidi; Rachid Frikh; Naoufal Hjira; Mohammed Boui
Journal:  Pan Afr Med J       Date:  2017-07-24

2.  Vogt-Koyanagi-Harada disease: a retrospective and multicentric study of 41 patients.

Authors:  K Diallo; S Revuz; G Clavel-Refregiers; T Sené; C Titah; M Gerfaud-Valentin; P Seve; R Jaussaud
Journal:  BMC Ophthalmol       Date:  2020-10-07       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.